Chattanooga Oncology Hematology Associates

Chattanooga, Tennessee 37804

0 studies enrolling now · 57 studies all time

What they study most

Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, Breast Neoplasms, Breast Tumor, Cancer of the Breast, Cancer of the Rectum, Carcinoma, Carcinoma, Small Cell, Carcinoma, Small Cell Lung, Chronic Lymphocytic Leukemia, Colorectal Cancer, ER+ Breast Cancer

Studies at this site

• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
• A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer — Completed
• Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer — Completed
• First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC — Completed
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) — Completed
• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer — Completed
• Vinflunine in Hormone Refractory Prostate Cancer (HRPC) — Completed
• 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer — Completed
• RAD001 Plus Bevacizumab in Metastatic Melanoma — Completed
• LBH589 Treatment for Refractory Clear Cell Renal Carcinoma — Completed
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer — Completed
• LBH589 in Refractory Myelodysplastic Syndromes (MDS) — Stopped early
• Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer — Completed
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer — Completed
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed
• A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer — Completed
• Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas — Completed
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed
• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy — Completed
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer — Completed
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer — Completed
• Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia — Completed
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy — Completed
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer — Completed
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma — Completed
• Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Completed
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma — Completed
• Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site — Completed
• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer — Completed
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib — Completed
• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer — Completed
• Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer — Completed
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC — Completed
• FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only — Completed
• Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma — Completed
• Trial of Poor Performance Status Patients (ToPPS) — Completed
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer — Completed
• A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma — Completed
• High-dose Bevacizumab in Advanced Renal Carcinoma Patients — Completed
• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer — Completed
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone — Completed
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma — Completed
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site — Completed
• Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site — Completed
• Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer — Completed
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma — Completed